FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Veru's Free Cash Flow for the
three
months ended in Dec. 2023 was $-6.02 Mil. Veru's Revenue for the
three
months ended in Dec. 2023 was $2.14 Mil. Therefore, Veru's FCF Margin % for the quarter that ended in Dec. 2023 was -281.18%.
The historical rank and industry rank for Veru's FCF Margin % or its related term are showing as below:
VERU'
s FCF Margin % Range Over the Past 10 Years
Min: -544.15 Med: -12.68 Max: 14.57
Current: -375.9
During the past 13 years, the highest FCF Margin % of Veru was 14.57%. The lowest was -544.15%. And the median was -12.68%.
VERU's FCF Margin % is ranked worse than 62.63% of 1033
companies
in the Biotechnology industry
Industry Median: -148.24
vs VERU: -375.90
Veru FCF Margin % Historical Data
The historical data trend for Veru's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Veru's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Veru's FCF Margin % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Veru's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Veru's FCF Margin % falls into.
Veru FCF Margin % Calculation
FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.
Veru's FCF Margin for the fiscal year that ended in Sep. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Veru FCF Margin % Related Terms
Thank you for viewing the detailed overview of Veru's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.
Veru Inc is a biopharmaceutical company with a drug development program for the treatment of metabolic diseases, oncology and acute respiratory distress syndrome (ARDS). The company is also in the late stage development of certain drugs for management of breast and prostate cancers. It also has a sexual health program which includes two products, ENTADFI, for the treatment of benign prostatic hyperplasia (BPH) and the FC2 Female Condom (Internal Condom). The company operates in single segment and generates revenue from USA which is the key revenue generating market, South Africa and other regions.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
VERU has been successfully added to your 